Sweden · Delayed Price · Currency is SEK Vicore Pharma Holding AB Earnings Call Transcripts
Fiscal Year 2026
-
A novel AT2 receptor agonist is advancing in a large phase II-B IPF trial, with strong early efficacy and safety signals, and enrollment completion expected in H1 2024. The therapy's unique mechanism and tolerability profile position it for frontline or combination use, with future expansion into other fibrotic diseases considered.
-
Buloxibutid, an oral AT2 receptor agonist, demonstrated unprecedented lung function improvement in IPF patients, with strong safety and tolerability in Phase 2a. The ongoing Phase 2b trial aims to confirm efficacy and broaden use as a frontline therapy, with enrollment completion expected in H1 2024.
-
Buloxibutid, an oral AT2 receptor agonist, is advancing in late-stage IPF development, showing promising efficacy and tolerability in phase II-A trials. A phase IIb study is underway, with top-line data expected in mid-2027 and sufficient cash runway through mid-2028.
-
A novel oral therapy targeting the AT2 receptor for IPF showed improved lung function and strong tolerability in a nine-month phase II-A study, with a large phase II-B/III trial underway. The approach addresses key disease mechanisms and aims to outperform current therapies.
Fiscal Year 2025
-
Buloxibutid, a first-in-class therapy for IPF, demonstrated promising efficacy and safety in phase IIa trials, with over 200 mL improvement in lung function and a favorable side effect profile. The ongoing phase IIb trial, now expanded to 360 patients, aims to confirm these results globally.
-
IPF remains a fatal disease with limited, incremental therapies and high unmet need. Buloxibutid, targeting the AT2 receptor, has shown promising lung function improvement and safety in early trials, with a robust phase II-B study underway and strong financial and partnership support.
-
The company is advancing a novel therapy for IPF targeting the angiotensin II type II receptor, showing promising phase IIA results with improved lung function. A large phase IIB trial is underway, with top-line data expected in 2027, and the company is well-funded to reach key milestones.
-
The company is advancing a novel AT2 receptor agonist for IPF, aiming to address both fibrosis and vascular dysfunction. Phase IIA data showed unprecedented lung function improvement, and a large global phase IIB trial is underway with results expected in 2027. Financially secure, the company is exploring flexible commercialization strategies.
-
A novel AT2 receptor agonist for IPF demonstrated strong preclinical and phase II-A results, with a 200 mL lung function improvement over 36 weeks and a favorable safety profile. A 52-week phase II-B trial is underway, aiming for broad adoption and future indication expansion.
-
A novel IPF therapy targeting epithelial repair, fibrosis, and vascular dysfunction showed strong lung function improvement in a phase IIa study, with a robust phase IIb trial underway. The company is well-funded, exploring U.S. listing, and has strategic partnerships in place.
-
A novel IPF therapy targeting the AT2 receptor showed strong safety and efficacy in phase 2a, with 65% of patients improving lung function. A global phase 2b trial is underway, supported by robust financials and investor backing.
-
Buloxibutid, an oral therapy for IPF, demonstrated strong efficacy and safety in phase IIA, with a robust phase IIB trial underway across 14 countries. Its upstream, multimodal mechanism offers potential advantages over current treatments, and future plans include broader pipeline expansion.
-
Buloxibutid, an AT2 receptor agonist, is being advanced for IPF, showing promising safety and efficacy in phase IIa with improved lung function and favorable tolerability. A global phase IIb trial is underway to confirm its potential as a frontline therapy.
-
A novel AT2 receptor agonist for IPF demonstrated strong efficacy and safety in phase 2a, with a large phase 2b trial underway and fast-track status granted. Mechanistic and translational data support its differentiated approach, and the company is well-funded to advance both this and additional fibrotic disease programs.
Fiscal Year 2024
-
Buloxibutid, an oral therapy targeting the AT2 receptor, showed durable lung function improvement and strong safety in phase IIa IPF trials, with a robust phase IIb underway. The company is well-capitalized, has a key pharma partnership, and is positioned to address significant unmet needs in IPF.
-
Buloxibutid's phase IIb ASPIRE trial for IPF is underway, powered for robust clinical endpoints and supported by a SEK 782 million rights issue to fund trial execution, manufacturing scale-up, and platform development. Recruitment strategies and study design aim for efficient enrollment and regulatory alignment.